Description

AZP-531 is an analogue of unacylated ghrelin designed to improve glycaemic control and reduce weight.–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Metabolism-sugar/lipid metabolism–C40H63N15O13—-[1]Julien M, et al. In vitro and in vivo stability and pharmacokinetic profile of unacylated ghrelin (UAG) analogues. Eur J Pharm Sci. 2012 Nov 20;47(4):625-35.|[2]Delhanty PJ, et al. Des-acyl ghrelin analogs prevent high-fat-diet-induced dysregulation of glucosehomeostasis. FASEB J. 2013 Apr;27(4):1690-700.|[3]Allas S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes. Diabetes Obes Metab. 2016 Sep;18(9):868-74.–1088543-62-7–962.02–98.54–O=C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H]1CCCNC(N)=N)=O)C(C)C)=O)CCC(N)=O)=O)CO)N(CCC2)[C@]2([H])C(N[C@H](C(N[C@H](C(N[C@H](C(N1)=O)CCC(N)=O)=O)CC3=CN=CN3)=O)CCC(O)=O)=O–Metabolic Disease; Endocrinology–H2O : 100 mg/mL (ultrasonic)–GHSR—-GPCR/G Protein–Peptides